Dec 24, 2025 • MarketBeat
NEUTRAL
Assenagon Asset Management S.A. Has $2 Million Holdings in Avidity Biosciences, Inc. $RNA
Assenagon Asset Management S.A. significantly increased its stake in Avidity Biosciences, Inc. (NASDAQ:RNA) during Q3, now holding 45,923 shares valued at $2.00 million. Other institutional investors like Norges Bank, Rhumbline Advisers, and Mirae Asset Global Investments also adjusted their holdings. Despite a Q3 loss of $1.27 per share, Avidity Biosciences, with a $10.87 billion market cap, saw revenue increase by 420.8% year-over-year and maintains a "Hold" consensus analyst rating.
Dec 20, 2025 • Investing.com
NEUTRAL
Avidity Biosciences stock hits all-time high at 72.23 USD
Avidity Biosciences Inc. (RNA) reached an all-time high of 72.23 USD, driven by significant investor confidence and strong financial performance. Despite this success, the company is undergoing a transition with Novartis acquiring it for approximately $12 billion, leading to analyst downgrades. Avidity has also launched a Managed Access Program for its Duchenne muscular dystrophy therapy.
Dec 20, 2025 • Investing.com Nigeria
SOMEWHAT-BULLISH
Avidity Biosciences stock hits all-time high at 72.23 USD By Investing.com
Avidity Biosciences Inc. (RNA) reached an all-time high of 72.23 USD, driven by significant investor confidence and strategic advancements in the biotechnology sector. The company maintains a strong financial position, evidenced by its substantial market capitalization and revenue growth. Recent developments include the launch of a Managed Access Program for a Duchenne muscular dystrophy therapy and an acquisition agreement with Novartis, leading to analyst downgrades despite the stock's strong performance.
Dec 19, 2025 • Investing.com South Africa
BULLISH
Avidity Biosciences stock hits all-time high at 72.23 USD By Investing.com
Avidity Biosciences (RNA) stock has reached an all-time high of $72.23, reflecting a remarkable surge in the past year and indicating strong investor confidence. This milestone follows the launch of a Managed Access Program for its investigational Duchenne muscular dystrophy therapy and the announcement of an acquisition by Novartis for approximately $12 billion. Following the acquisition news, several analyst firms downgraded Avidity Biosciences, adjusting price targets.
Dec 19, 2025 • MarketBeat
SOMEWHAT-BEARISH
Avidity Biosciences (NASDAQ:RNA) Lowered to Hold Rating by Evercore ISI
Avidity Biosciences (NASDAQ:RNA) has been downgraded to a "Hold" rating by Evercore ISI, with other firms also cutting ratings, resulting in a consensus "Hold" with an average price target of $69.57. The company missed Q3 EPS estimates, reporting ($1.27) against ($1.05) expected, despite a 420.8% revenue jump to $12.48M. Insiders have also sold approximately $1.5 million worth of shares recently, and the stock is trading near its one-year high.
Dec 18, 2025 • MLex
NEUTRAL
Novartis-Avidity Biosciences deal gets early clearance in US
Novartis and Avidity Biosciences have received early antitrust clearance from US competition authorities for their $12 billion deal. The agencies granted early termination of the Hart-Scott-Rodino Act waiting period on December 17, as confirmed by Avidity in a securities filing. This approval means the acquisition can proceed without further delay from US antitrust reviews.